Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome

Mexico is the First Latin American Country to Approve Treatment

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, February 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY)(TSX: SHQ), the global specialty biopharmaceutical company, announced that ELAPRASE(R) (idursulfase), a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved for commercial sale by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS). Mexico is the tenth-largest pharmaceutical market in the world(1) and the first Latin American country to approve ELAPRASE.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a serious, life-threatening genetic condition mainly affecting males that results from an absence of, or deficiency in, the lysosomal enzyme iduronate-2-sulfatase. Without sufficient amounts of this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction, leading to severe clinical complications and early mortality.

ELAPRASE, developed by Shire Human Genetic Therapies (HGT), is the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. The medicine is given as a weekly infusion and is designed to replace the deficient iduronate-2-sulfatase enzyme.

"The approval of ELAPRASE in Mexico marks a significant milestone because for the first time, Hunter syndrome patients in Mexico have access to treatment," said Sylvie Gregoire, President of Shire HGT, the Shire business unit focused on genetic diseases. "This approval also underscores our dedication and commitment to provide meaningful treatments for patients suffering from serious and often neglected diseases around the world."

"Hunter syndrome is a devastating disease and until now, Mexican citizens had no viable treatment," said Dr. Luis Figuera Villanueva, Title C Investigator, Division of the Genetic Center of Western Biomedical, Investigator of the IMSS and Professor of Human Genetics for the Central University of Heath Sciences, University of Guadalajara. "As a physician, it's exciting and rewarding to now be able help these patients and their families and offer them hope for a brighter future."

Since its U.S. approval in July 2006, ELAPRASE has been approved for marketing and commercial distribution in 37 countries worldwide including countries in Europe and Japan. Shire expects to launch the product in Mexico within the first half of 2008.

Notes to Editors


ELAPRASE is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

Shire Human Genetic Therapies is actively tracking health data among individuals affected by Hunter syndrome as part of the company's long-term outcome survey, called the Hunter Outcome Survey (HOS). HOS is designed to support the gathering, analysis, reporting and sharing of data from around the world about Hunter syndrome. Shire believes that the inclusion of all people affected by Hunter syndrome, whether on therapy or not, and the analysis and dissemination of this information will allow for further understanding of Hunter syndrome and disease education on a global scale.

More information about ELAPRASE and Hunter syndrome is available at or

About Hunter Syndrome

Hunter syndrome (MPS II) is a serious genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans or GAG. Hunter syndrome is one of several related lysosomal storage diseases.

In Hunter syndrome, cumulative build up of GAG in cells throughout the body interferes with the way certain tissues and organs function, leading to severe clinical complications and early mortality. Physical manifestations for some people with Hunter syndrome may include distinct facial features, a large head and an enlarged abdomen. People with Hunter syndrome may also experience hearing loss, thickening of the heart valves leading to a decline in cardiac function, obstructive airway disease, sleep apnea, and enlargement of the liver and spleen. In some cases, central nervous system involvement leads to progressive neurologic decline.

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development (including the successful development of JUVISTA(R) (Human TGFb3)), manufacturing and commercialization (including the launch and establishment in the market of VYVANSE(TM)); the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.


(1) Epsicom Business Intelligence. (June 30, 2007) The Pharmaceutical Market: Mexico

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... ... 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem ... from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the early ... is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of ...
(Date:10/7/2015)... N.Y. , Oct. 7, 2015   PDI ... today released an infographic that highlights key challenges across ... an appropriate disinfectant for the situation. This tool is ... steps hospitals can take to create efficiencies and lower ... The visual guide emphasizes examples of how to ...
Breaking Biology Technology:
... the people who helped North Carolina and Los Angeles ... communities of angel investors shared their most effective practices ... , ,Their techniques included educational programsbut you have to ... of the Council for Entrepreneurial Development , based ...
... Educating and advising potential angel investors, or cherubs, ... seraphs was the goal of a seminar at the ... titled Private Equity and Angel Investing Boot Camp, exposed ... resources and initiatives customized to help burgeoning investors make ...
... new leading security solution that combines networking infrastructure and ... approach to security. It is a logical step in ... imperatives from an IT perspective have been focused on ... components of network security. But more recently, with an ...
Cached Biology Technology:
(Date:9/8/2015)... 8, 2015  Affectiva, global leader in emotion-sensing ... Service, a new data solution, and version 2.0 ... Affectiva,s highly accurate and patented science, these new ... to transform industries such as market research, gaming, ... experience, online education, HR, automotive, robotics, healthcare and ...
(Date:9/2/2015)... 2, 2015 Security of data and ... banks, government organizations, telecommunications, hospitals, as well as ... previously being used to prevent unauthorised access. Technological ... wherein individuals could gain access to secure premises ... as hardware devices and numeric codes. However, hackers ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
Breaking Biology News(10 mins):
... one of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . A ... Bioengineering and Biotechnology will provide a single open-access ... to be disseminated and discussed. Frontiers ...
... U.S. Forest Service scientists are part of "Landscapes ... the TKF Foundation, will examine how collaborative planning and ... from tragedy. , The TKF Foundation announced today that ... for grant funding. In addition to research on the ...
... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ...
Cached Biology News:
... The 7500ce meets the demands of ... require high performance from reliable, robust and ... unmatched detection power in the most challenging ... It is equally suited to the toughest ...
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... LC Sciences provides a comprehensive ... small regulatory/functional RNA embedded within non-coding ... technology and proprietary probe design, which ... detection of small RNAs (1). This ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: